SNPHF (Santen Pharmaceutical Co) Other Stockholders Equity: $355 Mil (As of Mar. 2026)


SNPHF Santen Pharmaceutical Co Ltd SNPHF
81 GF Score
Price $13.05
GF Value $10.25
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Santen Pharmaceutical Co Other Stockholders Equity?

Santen Pharmaceutical Co SNPHF +4.40% 81 Other Stockholders Equity is $355 Mil as of Mar. 2026. GuruFocus rates SNPHF with a GF Score™ of 81/100 and a GF Value™ of $10.25 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Santen Pharmaceutical Co's Other Stockholders Equity for the quarter that ended in Mar. 2026 was $355 Mil.

Santen Pharmaceutical Co's quarterly Other Stockholders Equity increased from Sep. 2025 ($330 Mil) to Dec. 2025 ($388 Mil) but then declined from Dec. 2025 ($388 Mil) to Mar. 2026 ($355 Mil).

Santen Pharmaceutical Co's annual Other Stockholders Equity declined from Mar. 2024 ($323 Mil) to Mar. 2025 ($272 Mil) but then increased from Mar. 2025 ($272 Mil) to Mar. 2026 ($355 Mil).

Santen Pharmaceutical Co Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Santen Pharmaceutical Co's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santen Pharmaceutical Co Other Stockholders Equity Chart

Santen Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 250.36 282.66 323.14 271.77 354.57

Santen Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 271.77 304.15 329.60 388.30 354.57
SNPHF
81GF Score
Santen Pharmaceutical Co Ltd SNPHF
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santen Pharmaceutical Co Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $355 Mil mean?
Santen Pharmaceutical Co (SNPHF) has a Other Stockholders Equity of $355 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Santen Pharmaceutical Co and its competitors.
Is Santen Pharmaceutical Co's Other Stockholders Equity too high?
Santen Pharmaceutical Co's current Other Stockholders Equity is $355 Mil. Overall, Santen Pharmaceutical Co has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's Other Stockholders Equity compare to LLY and JNJ?
Santen Pharmaceutical Co's Other Stockholders Equity of $355 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Santen Pharmaceutical Co and its competitors. Santen Pharmaceutical Co's current Other Stockholders Equity is $355 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHF) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.25, compared to a current price of $13.05 — trading 27.3% above its estimated fair value. The current Other Stockholders Equity is $355 Mil. Santen Pharmaceutical Co's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHF), the current Other Stockholders Equity is $355 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santen Pharmaceutical Co (SNPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued. The current stock price of $13.05 is trading 27.3% above its estimated GF Value™ of $10.25. GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SNPHF:

  • Other Stockholders Equity: $355 Mil
  • GF Value™: $10.25 vs. price of $13.05 (27.3% above fair value)
  • GF Score™: 81/100 with 6 warning signs

No single metric tells the full story. See the SNPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Santen Pharmaceutical Co Business Description

Other Exchanges SNPHY:USA4536:Japan
Address 4-20 Ofukacho, Grand Front Osaka Tower A, Kita-ku, Osaka Prefecture, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
81GF Score

Get the complete analysis for SNPHF

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.05
Price
$10.25
GF Value